Bulletin
Investor Alert

HilleVax Inc.

NAS: HLVX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
HilleVax Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 31, 2023, 5:09 p.m.

HLVX
/zigman2/quotes/234952647/composite

$

16.53

Change

0.00 0.00%

Volume

Volume 5,556

Quotes are delayed by 20 min

/zigman2/quotes/234952647/composite

Previous close

$ 16.20

$ 16.53

Change

+0.33 +2.04%

Day low

Day high

$15.51

$16.71

Open

52 week low

52 week high

$7.90

$24.42

Open

Company Description

HilleVax, Inc. operates as a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infe...

HilleVax, Inc. operates as a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was founded by Dr. Maurice Hilleman and Dr. Tadataka Yamada on 3rd March, 2020 and is headquartered in Boston, MA.

Valuation

Price to Book Ratio

2.36

Enterprise Value to EBITDA

-6.08

Efficiency

Liquidity

Current Ratio

22.28

Quick Ratio

22.28

Cash Ratio

21.42

Profitability

Return on Assets

-71.93

Return on Equity

-192.00

Return on Total Capital

-34.66

Capital Structure

Total Debt to Total Assets

11.47

Officers and Executives

Name Age Officer Since Title
Dr. Robert M. Hershberg 57 2020 Chairman, President & Chief Executive Officer
Dr. Aditya Kohli 33 2021 Chief Operating Officer & Director
Dr. Astrid Borkowski - 2021 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/01/2023 Robert M. Hershberg
President and CEO; Director 		187,966   Award at $0 per share. 0
02/01/2023 Aditya Kohli
Chief Operating Officer; Director 		85,466   Award at $0 per share. 0
02/01/2023 Astrid Borkowski
Chief Medical Officer 		51,333   Award at $0 per share. 0
02/01/2023 Shane Maltbie
Chief Financial Officer 		43,333   Award at $0 per share. 0
11/30/2022 Takeda Pharmaceutical Co., Ltd.
5,883,500   0
05/03/2022 Frazier Management LLC
1,764,706   Acquisition at $17 per share. 30,000,002
05/03/2022 Frazier Management LLC
2,736,234   Derivative/Non-derivative trans. at $13.6 per share. 37,212,782
/news/latest/company/us/hlvx

MarketWatch News on HLVX

  1. HilleVax started at buy with $34 stock price target at Stifel Nicolaus

    7:50 a.m. May 24, 2022

    - Tomi Kilgore

  2. HilleVax started at overweight with $24 stock price target at J.P. Morgan

    7:11 a.m. May 24, 2022

    - Tomi Kilgore

/news/nonmarketwatch/company/us/hlvx

Other News on HLVX

  1. 10-K: HILLEVAX, INC.

    4:19 p.m. March 17, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. Top 5 4th Quarter Trades of Abingworth LLP

    11:00 a.m. Feb. 12, 2023

    - GuruFocus.com

  6. HilleVax reports Q3 results

    12:30 p.m. Nov. 11, 2022

    - Seeking Alpha

  7. Abingworth LLP Buys 2, Sells 3 in 3rd Quarter

    9:00 p.m. Nov. 10, 2022

    - GuruFocus.com

  8. 10-Q: HILLEVAX, INC.

    6:24 p.m. Nov. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  9. Samsara BioCapital, LLC's Top 5 Buys of the 2nd Quarter

    11:00 p.m. Aug. 15, 2022

    - GuruFocus.com

  10. StepStone Group LP Buys 3, Sells 2 in 2nd Quarter

    3:00 p.m. Aug. 14, 2022

    - GuruFocus.com

  11. 10-Q: HILLEVAX, INC.

    4:34 p.m. Aug. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  12. Biotech Public Offerings at 10-Year Low

    3:56 p.m. July 11, 2022

    - GuruFocus.com

  13. Norovirus vaccine developer HilleVax stock jumps 23%

    4:10 p.m. June 23, 2022

    - Seeking Alpha

  14. 10-Q: HILLEVAX, INC.

    4:28 p.m. June 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  15. HilleVax stock jumps 11% following four analyst buy ratings

    1:25 p.m. May 24, 2022

    - Seeking Alpha

  17. HilleVax prices IPO at $17 per share, debuts today

    7:36 a.m. April 29, 2022

    - Seeking Alpha

  19. Novovirus vaccine developer HilleVax files for $100M IPO

    3:15 p.m. April 18, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

HilleVax, Inc.

75 State Street

Suite 100

Boston, Massachusetts 02109

Phone

1 6172135054

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

N/A

Net Income

$-159.81M

Employees

62.00

Annual Report for HLVX

/news/pressrelease/company/us/hlvx

Press Releases on HLVX

  5. HilleVax to Participate in November Investor Conferences

    7:30 p.m. Nov. 10, 2022

    - GlobeNewswire

  15. Penny Stocks To Watch: Ostin Tech (OST) Stock Nosedives Post IPO

    10:33 a.m. April 29, 2022

    - Penny Stocks

  16. HilleVax Announces Pricing of Upsized Initial Public Offering

    9:04 p.m. April 28, 2022

    - GlobeNewswire

Link to MarketWatch's Slice.